When: Current price at $443.84 with extended metrics (RSI 75.6, +27% above 200 SMA)

Then: Do NOT add new capital

HOLD

• Price pressing upper Bollinger Band at $449.46 with only 1% buffer - not a setup to get aggressive
• Stock up 18.5% in 30 days and over 51% in a year - rerating has already played out
• Forward earnings $24.40 versus trailing $16.08 - market has already priced in 52% earnings growth; if growth comes in at realistic 5-8% sustainable rate, the multiple is not attractive
• Adding on strength at 85% of 52-week high with RSI over 75 is momentum chasing, not risk management
• Macro consensus (86% odds of no rate cuts, 8% recession probability) is already in the price; without easy policy tailwind, market needs genuine earnings beats
• Beta of 0.41 doesn't protect against company-specific shocks; biotech FDA events can gap stock 5-8% overnight regardless of beta
• Patent cliff and IRA risk not fully quantifiable - tail risks with fat tails that can materialize violently
• Support trader's plan: hold core, trail stop tighter than $395, trim into strength above $450, wait for pullback to $405-425 or confirmed breakout before adding
• Recommends tighter stop at $426 (10 EMA) or $422 (two ATR below) instead of current $395 stop
• Collect 2.29% dividend yield while waiting for better entry setups
• Goal is to protect existing gains, not chase additional gains in late-cycle technical conditions

→ vs aggressive: The 'don't fade overbought RSI' argument is survivorship bias - you don't know in real time which overbought trend continues versus which snaps back to the 20-day moving average

→ vs aggressive: Argus raising price target from $375 to $460 is already in the price; calling $480-500 because 'consensus is catching up' is exactly what people said at market tops in prior cycles

→ vs aggressive: Adding on strength at 85% of 52-week high with RSI over 75 and price pressed against upper Bollinger Band is how you turn a winning position into a break-even one

→ vs aggressive: Macro consensus view (86% no rate cuts, 8% recession probability) is already in the price; soft landing with no rate cuts means the easy policy tailwind is gone

→ vs aggressive: Patent cliffs and IRA risk are not fully priced because they're not quantifiable - you can't model exactly when biosimilar erosion or Medicare negotiation impact hits

→ vs aggressive: Calling $395 stop 'generous' is wrong for a stock up 51% in a year showing late-cycle technical conditions; an 11% drawdown can come fast and should be protected with a tighter stop

HOLD with refined execution parameters

• HOLD decision is correct but requires tighter execution
• Tighten trailing stop to hybrid framework: close below 10 EMA at $426, or hard floor at $410, whichever is higher
• Codify trim discipline: trim 25% of position on confirmed close above $445 with volume
• Reject aggressive analyst's instinct to add on strength—entry discipline matters even in strong trends
• Reject conservative analyst's instinct to pre-sell based on overbought readings while ignoring trend-confirming technicals
• 2.29% dividend yield and 0.41 beta support a 'be paid to wait' approach
• Patent cliffs and IRA pricing are structural overhangs requiring position sizing for 5% gap-down scenario
• The trader's framework of waiting for breakout confirmation or pullback reset is the correct middle path

→ vs aggressive: Entry point does matter—adding at extended levels invites 3-5% shakeouts that punish anyone who added at the upper Bollinger Band; $480 and $500 price targets lack foundation and are unfalsifiable

→ vs conservative: Cannot selectively cite overbought warnings while ignoring MACD expansion, volume-confirmed VWMA up 27% since May, and higher highs/lower lows sequence that confirm intact trend